B2B only. For licensed importers and distributors. Tender authorities and healthcare institutions are also served. Not for retail or patient supply.  ·  Compliance statement
Home/Insights/Product comparison
Product comparison

IVIG 5% vs 10%: what's the difference

The percentage is the protein concentration — 50 mg per millilitre versus 100 mg per millilitre — and it changes the infusion volume, the infusion time and the fluid load. It also marks a route-of-administration boundary that matters more than the number.

A specification that says only "IVIG" is not yet complete, because intravenous immunoglobulin is supplied at more than one concentration — most commonly 5% and 10% — and the concentration is not a cosmetic label. It changes the infusion volume, the infusion time and the fluid load, and it sits next to a route-of-administration distinction (intravenous versus intramuscular) that must not be blurred. A buyer who quotes "10%" when the protocol specifies 5% — or worse, who treats an intramuscular 10% product as a higher-strength substitute for intravenous use — has placed the wrong medicine on the line.

This comparison is written for licensed importers, distributors and tender authorities. It explains what the concentration means, how the presentations differ, and what wanyoda supplies, so the quoting stage is unambiguous.

The one-sentence difference

The percentage is the immunoglobulin concentration: a 5% solution contains 50 mg of immunoglobulin per millilitre, and a 10% solution contains 100 mg per millilitre. A 10% product therefore delivers the same protein dose in half the fluid volume — a smaller infusion, but not automatically a "better" or interchangeable one.

Side-by-side comparison

Dimension IVIG 5% IVIG 10%
Protein concentration 50 mg / ml 100 mg / ml
Volume for equal dose Larger Half (smaller)
Typical infusion time Longer (larger volume) Potentially shorter
Fluid load Higher Lower
Route Intravenous Intravenous
wanyoda portfolio Supplied (2.5 g / 50 ml · 5 g / 100 ml) Not supplied as IVIG

One caution belongs directly under this table: a 10% human immunoglobulin for intramuscular use exists as a separate product, and it is not the same medicine as 10% IVIG. Route of administration is a clinical and regulatory distinction, not a concentration detail. The two must not be conflated on a tender line.

Why the difference matters at procurement

The distinction shows up in three places the buying side has to get right.

Separate tender lines

Different concentrations are different presentations, and intravenous and intramuscular products are different medicines with different approval numbers. They appear as separate lines, and they are not interchangeable within a line. A specification should name the concentration and the route.

Fluid load is a clinical variable

A 5% product delivers the same protein dose in a larger volume than a 10% product. For patients who are fluid-restricted — in renal or cardiac impairment, for example — the lower-volume, higher-concentration option may reduce the fluid burden. This is a clinical consideration, and it belongs on the specification rather than in the buyer's discretion.

Infusion logistics

The concentration affects how the product is administered and how long an infusion takes. That, in turn, affects ward capacity and scheduling. The distinction is practical, not just pharmaceutical, and it should be reflected in the tender's operational requirements.

What wanyoda supplies

wanyoda supplies IVIG as a 5% solution for intravenous administration, in 2.5 g / 50 ml and 5 g / 100 ml single-dose vials, stored at 2–8 °C and protected from light, and must not be frozen. A 10% IVIG presentation is not part of the current portfolio, and the 10% intramuscular immunoglobulin is a separate product outside the intravenous line.

If a specification calls for 10% IVIG, the buyer should confirm the exact product and manufacturer; wanyoda's 5% IVIG should not be quoted as a concentration substitute. If the requirement is 5% IVIG, wanyoda can quote directly with the approval reference and registration dossier.

How to decide which one you need

Three questions resolve the specification:

  • Does the tender name a concentration (5% or 10%)? Match it exactly — the concentration is not negotiable.
  • Does the tender name a route (intravenous or intramuscular)? The route decides the product class, and an IM product is never a substitute for IVIG.
  • Is the specification ambiguous? Stop and ask for the concentration and route before quoting — guessing is how a wrong medicine is placed.

Frequently asked questions

What does IVIG 5% vs 10% mean?

The percentage is the immunoglobulin concentration: a 5% solution contains 50 mg of immunoglobulin per millilitre, and a 10% solution contains 100 mg per millilitre. A 10% product delivers the same protein dose in half the fluid volume.

Which IVIG concentration does wanyoda supply?

wanyoda supplies IVIG as a 5% solution for intravenous administration — 2.5 g / 50 ml and 5 g / 100 ml presentations. A 10% preparation for intramuscular use is a different product with a different route of administration, not a higher-strength substitute for intravenous use.

Is a 10% IVIG faster to infuse?

Generally, a higher concentration delivers the same protein dose in a smaller volume, which can allow a shorter infusion time and a lower fluid load. However, concentration is not a substitute for a clinical decision — infusion rate is set by the prescribing protocol and the patient's tolerance, not by the buyer.

Why does fluid load matter in IVIG?

A lower concentration means a larger infusion volume for the same protein dose. For patients who are fluid-restricted — for example in renal or cardiac impairment — the higher concentration may reduce the fluid burden. This is a clinical consideration that belongs on the specification.

Are 5% and 10% IVIG interchangeable?

Not automatically. They are different concentrations with different volumes, infusion characteristics and fluid loads, and a 10% intramuscular product is a different medicine altogether. The specified concentration should be confirmed with the prescribing protocol before quoting.

Where to go next

Sourcing

Specify the right concentration on the right line.

Tell us the concentration, route and destination market, and we will confirm the matching product, approval reference and registration dossier.